Immunocore Holdings (IMCR) Cash from Operations (2021 - 2026)

Immunocore Holdings (IMCR) has reported Cash from Operations for 6 consecutive years, with 13775000.0 the latest figure, recorded in Q1 2026.

• Quarterly Cash from Operations fell 3266.67% year-over-year to 13775000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24922000.0 (down 180.18% YoY) and the FY2025 annual result came in at 10712000.0, down 141.1% from the prior year.
• Cash from Operations grew to 13775000.0 in Q1 2026 per IMCR's latest filing, from 32655000.0 in the prior quarter.
• Over the last five years, Cash from Operations for IMCR reached as high as 25964000.0 in Q2 2025 and fell as low as 32655000.0 in Q4 2025.
• A 5-year average of 1408551.57 and a median of 435000.0 in 2025 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2024 — Cash from Operations soared 52060.0% — and 2026, when it tumbled 3266.67%.
• Year by year, Cash from Operations stood at 7075103.63 in 2022, then tumbled by 350.64% to 17733000.0 in 2023, then rose by 21.33% to 13951000.0 in 2024, then sank by 134.07% to 32655000.0 in 2025, then jumped by 57.82% to 13775000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 13775000.0, 32655000.0, and 4456000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.